Edition:
United States

Pfizer Inc (PFE)

PFE on New York Consolidated

34.17USD
23 Jun 2017
Change (% chg)

$0.11 (+0.32%)
Prev Close
$34.06
Open
$34.08
Day's High
$34.22
Day's Low
$33.97
Volume
30,046,310
Avg. Vol
22,973,015
52-wk High
$37.39
52-wk Low
$29.83

PFE

Chart for PFE

About

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business... (more)

Overall

Beta: 0.99
Market Cap(Mil.): $203,486.70
Shares Outstanding(Mil.): 5,955.13
Dividend: 0.32
Yield (%): 3.75

Financials

  PFE Industry Sector
P/E (TTM): 28.64 14.09 19.01
EPS (TTM): 1.19 -- --
ROI: 5.28 -6.73 -5.03
ROE: 12.02 -6.18 -4.28

Novartis breast cancer drug Kisqali wins European panel backing

ZURICH A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.

Jun 23 2017

Novartis breast cancer drug Kisqali wins European panel nod

ZURICH, June 23 A European Medicines Agency (EMA) panel recommended on Friday approving Novartis's Kisqali drug, bolstering the Swiss drugmaker's bid to challenge rival Pfizer's Ibrance against tough-to-treat breast cancer.

Jun 23 2017

BRIEF-Pfizer sets quarterly dividend of $0.32 per share

* Sets quarterly dividend of $0.32 per share Source text for Eikon: Further company coverage:

Jun 22 2017

Nestle's Gerber baby food unit on the lookout for acquisitions

LONDON/ZURICH, June 22 Nestle's Gerber baby food business could make acquisitions and sign partnerships with innovative startups to fuel growth in its home market, the United States, and in the fast-growing Chinese market, the division's head told Reuters

Jun 22 2017

BRIEF-Pfizer receives Health Canada approval for Ibrance in hr+, her2- metastatic breast cancer

* Pfizer receives expanded Health Canada approval for ibrance in hr+, her2- metastatic breast cancer Source text for Eikon: Further company coverage:

Jun 21 2017

BRIEF-Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer

* Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer

Jun 20 2017

BRIEF-Pfizer begins Phase 1 clinical trial to evaluate investigational Group B streptococcus vaccine

* Pfizer begins Phase 1 clinical trial to evaluate investigational Group B streptococcus vaccine

Jun 19 2017

BRIEF-U.S. FDA updates on Pfizer drug shortages

* Says it is aware of the ongoing shortage situation affecting several injectable drugs, manufactured by Hospira, a Pfizer company

Jun 15 2017

BRIEF-Basilea announces license agreement with Pfizer for antifungal Cresemba

* Basilea announces license agreement with Pfizer for antifungal Cresemba® (isavuconazole) for Europe, Russia, Turkey And Israel

Jun 14 2017

BRIEF-Pfizer to have exclusive rights to distribute, commercialize CRESEMBA in Europe

* Pfizer receives exclusive commercialization rights in Europe for CRESEMBA, a novel treatment for potentially life-threatening fungal infections among immunocompromised patients

Jun 14 2017

More From Around the Web

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $136.43 +0.38
Novartis AG (NOVN.S) CHF83.70 -0.10
Merck & Co., Inc. (MRK.N) $66.16 +0.14
Roche Holding Ltd. (ROG.S) CHF252.80 0.00
Roche Holding Ltd. (RO.S) CHF254.25 -1.75
Abbott Laboratories (ABT.N) $49.08 -0.19
Bayer AG (BAYGn.DE) €121.90 -0.60
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €87.87 -0.78
AstraZeneca plc (AZN.L) 5,401.00 -107.00

Earnings vs. Estimates